title: Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
abstract: BACKGROUND
  Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these patients. The aim of this study was to evaluate the predictive capacity of biochemical markers of bone turnover for mortality risk, disease progression and SREs in patients with PCa and bone metastases undergoing treatment with zoledronic acid (ZA).
  
  
  METHODS
  This was an observational, prospective and multicenter study in which ninety-eight patients were included. Patients were treated with ZA (4 mg every 4 weeks for 18 months). Data were collected at baseline and 3, 6, 9, 12, 15 and 18 months after the beginning of treatment. Serum levels of bone alkaline phosphtase (BALP), aminoterminal propeptide of procollagen type I (P1NP) and beta-isomer of carboxiterminal telopeptide of collagen I (β-CTX) were analysed at all points in the study. Data on disease progression, SREs development and survival were recorded.
  
  
  RESULTS
  Cox regression models with clinical data and bone markers showed that the levels of the three markers studied were predictive of survival time, with β-CTX being especially powerful, in which a lack of normalisation in visit 1 (3 months after the beginning of treatment) showed a 6.3-times more risk for death than in normalised patients. Levels of these markers were also predictive for SREs, although in this case BALP and P1NP proved to be better predictors. We did not find any relationship between bone markers and disease progression.
  
  
  CONCLUSIONS
  In patients with PCa and bone metastases treated with ZA, β-CTX and P1NP can be considered suitable predictors for mortality risk, while BALP and P1NP are appropriate for SREs. The levels of these biomarkers 3 months after the beginning of treatment are especially important.
authors.affiliation: Bioquímica Investigación, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain. cpiedra@fjd.es
authors.forename: C
authors.initials: C
authors.lastname: de la Piedra
authors.forename: A
authors.initials: A
authors.lastname: Alcaraz
authors.forename: J
authors.initials: J
authors.lastname: Bellmunt
authors.forename: C
authors.initials: C
authors.lastname: Meseguer
authors.forename: A
authors.initials: A
authors.lastname: Gómez-Caamano
authors.forename: M J
authors.initials: MJ
authors.lastname: Ribal
authors.forename: F
authors.initials: F
authors.lastname: Vázquez
authors.forename: U
authors.initials: U
authors.lastname: Anido
authors.forename: P
authors.initials: P
authors.lastname: Samper
authors.forename: E
authors.initials: E
authors.lastname: Esteban
authors.forename: J L
authors.initials: JL
authors.lastname: Álvarez-Ossorio
authors.forename: P C
authors.initials: PC
authors.lastname: Lara
authors.forename: L A
authors.initials: LA
authors.lastname: San José
authors.forename: J A
authors.initials: JA
authors.lastname: Contreras
authors.forename: A G
authors.initials: AG
authors.lastname: del Alba
authors.forename: B
authors.initials: B
authors.lastname: González-Gragera
authors.forename: A J
authors.initials: AJ
authors.lastname: Tabernero
authors.forename: C
authors.initials: C
authors.lastname: González-Enguita
authors.forename: J M
authors.initials: JM
authors.lastname: Fernández
authors.forename: A
authors.initials: A
authors.lastname: García-Escudero
authors.forename: F
authors.initials: F
authors.lastname: Gómez-Veiga
authors.forename: M J
authors.initials: MJ
authors.lastname: Méndez
authors.forename: J
authors.initials: J
authors.lastname: Segarra
authors.forename: J A
authors.initials: JA
authors.lastname: Virizuela
authors.forename: J
authors.initials: J
authors.lastname: Carles
authors.forename: A
authors.initials: A
authors.lastname: Lassa
authors.forename: V
authors.initials: V
authors.lastname: Calderero
authors.forename: M
authors.initials: M
authors.lastname: Constela
authors.forename: D
authors.initials: D
authors.lastname: Delgado
authors.forename: A
authors.initials: A
authors.lastname: Mañas
authors.forename: A
authors.initials: A
authors.lastname: Murias
authors.forename: G
authors.initials: G
authors.lastname: Reynes
authors.forename: B
authors.initials: B
authors.lastname: Rodriguez
authors.forename: G
authors.initials: G
authors.lastname: Rubio
authors.forename: E
authors.initials: E
authors.lastname: Sánchez
authors.forename: M
authors.initials: M
authors.lastname: Unda
authors.forename: E
authors.initials: E
authors.lastname: Solsona
authors.forename: J M
authors.initials: JM
authors.lastname: Martínez-Javaloyas
authors.forename: J
authors.initials: J
authors.lastname: Comet-Batlle
authors.forename: C
authors.initials: C
authors.lastname: Quicios
authors.forename: M
authors.initials: M
authors.lastname: Martín-Fernández
authors.forename: I
authors.initials: I
authors.lastname: Mahillo-Fernández
authors.forename: J
authors.initials: J
authors.lastname: Morote
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000032:analysis / Q000097:blood / Q000378:metabolism; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology; D004164:Diphosphonates / Q000627:therapeutic use*; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D012307:Risk Factors; D016019:Survival Analysis; D000077211:Zoledronic Acid
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid